Company profile
LARIMAR THERAPEUTICS, INC.
NASDAQ:LRMRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NOMLABOFUSP | phase3 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05579691 | phase2 | completed | 2022-09-21 | 2023-12-04 | Larimar Therapeutics, Inc. | A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia |
| NCT06681766 | phase1 | terminated | 2024-12-06 | 2025-04-27 | Larimar Therapeutics, Inc. | A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia |
| NCT07778836 | phase3 | recruiting | 2026-10-26 | 2029-07-01 | Larimar Therapeutics, Inc. | A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia |
| NCT06447025 | phase2 | recruiting | 2024-01-25 | 2027-01-01 | Larimar Therapeutics, Inc. | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia |
| NCT04519567 | phase1 | completed | 2020-07-31 | 2021-03-16 | Larimar Therapeutics, Inc. | Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia |
FDA applications (0)
No records yet.